BTLA and renal carcinoma: Given the negative correlation of CD160 expression with clinical prognosis in ESCC and other tumours such as renal cancer (Supplementary Fig. 8e), we postulate that CD160-expressing cancer cells could use the HVEM and BTLA inhibitory pathways to inhibit T and NK cells activities47,48.